HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER

Clinical trials for HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER explained in plain language.

Never miss a new study

Get alerted when new HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER trials appear

Sign up with your email to follow new studies for HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Early test of cancer Drug's immune effects halted

Knowledge-focused Terminated

This early study aimed to see how a single dose of an experimental drug called HB-201 affects the immune system in people with HPV 16+ head/neck or cervical cancer. It was given to 10 participants in the short window between their cancer diagnosis and their scheduled surgery or c…

Matched conditions: HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER

Phase: EARLY_PHASE1 • Sponsor: Hookipa Biotech GmbH • Aim: Knowledge-focused

Last updated Apr 01, 2026 14:43 UTC

HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER

Get alerted when new HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER trials appear

Early test of cancer Drug's immune effects halted